Cargando…
Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations
Anakinra (Kineret), a recombinant form of human interleukin-1 (IL-1) receptor antagonist, is approved for the treatment of rheumatoid arthritis (RA) in combination with methotrexate. Kineret is self-administered by daily subcutaneous injections in patients with active RA. The mechanism of action of...
Autores principales: | Kaiser, Christina, Knight, Ann, Nordström, Dan, Pettersson, Tom, Fransson, Jonas, Florin-Robertsson, Ebba, Pilström, Björn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264859/ https://www.ncbi.nlm.nih.gov/pubmed/21881988 http://dx.doi.org/10.1007/s00296-011-2096-3 |
Ejemplares similares
-
Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005) -
Experience of one UK site presenting a closer examination of safety and efficacy of Anakinra (Kineret(®)) in systemic juvenile idiopathic arthritis
por: Livermore, P, et al.
Publicado: (2008) -
PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013) -
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014) -
Effect of the IL-1 Receptor Antagonist Kineret(®) on Disease Phenotype in mdx Mice
por: Benny Klimek, Margaret E., et al.
Publicado: (2016)